Abstract Peginterferon-based therapy for chronic hepatitis B is known to cause leukopenia, neutropenia, and thrombocytopenia, but the relationship of early hematologic trajectories to serological response, supportive management, and whole-blood molecular signals remains uncertain. We conducted an exploratory hematologic safety-focused secondary analysis of a prospective, single-center cohort of 21 patients receiving peginterferon alfa-2b-based therapy (13 responders and 8 non-responders).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile